Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD). No liver injury has been observed with tolvaptan treatment in healthy subjects and in non-ADPKD indications, but ADPK...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Toxicol Sci
Hauptverfasser: Woodhead, Jeffrey L., Brock, William J., Roth, Sharin E., Shoaf, Susan E., Brouwer, Kim L.R., Church, Rachel, Grammatopoulos, Tom N., Stiles, Linsey, Siler, Scott Q., Howell, Brett A., Mosedale, Merrie, Watkins, Paul B., Shoda, Lisl K.M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2017
Schlagworte:
Mechanisms of Tolvaptan-Induced Liver Injury
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5216653/
https://ncbi.nlm.nih.gov/pubmed/27655350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/toxsci/kfw193
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge